肾衰方联合羟苯磺酸钙对慢性肾脏病疗效的研究

目的:观察肾衰方联合羟苯磺酸钙对各期慢性肾脏疾病(CKD)的影响。方法:肾小球滤过率(eGFR)低于每分钟60mL/1.73m2且未行透析治疗的慢性肾功能不全患者120例,分为羟苯磺酸钙组(31例)、肾衰方联合羟苯磺酸钙组(59例)、肾衰方组(30例)。羟苯磺酸钙组和肾衰方联合羟苯磺酸钙组采用羟苯磺酸钙组胶囊500mg,每日3次口服;肾衰方联合羟苯磺酸钙组和肾衰方组采用肾衰方50mL,每日3次口服。分别于治疗前及治疗后第2周观察各组患者血肌酐(Scr)、尿素氮(BUN)、肌酐清除率(Ccr)。结果:①肾衰方联合羟苯磺酸钙组(CKD III期、IV期、Ⅴ期)治疗2周后BUN下降(P<0.01),Scr显著下降(P<0.001),Ccr明显上升(P<0.001);②羟苯磺酸钙组(CKDIII期、IV期)在治疗后BUN、Scr下降,Ccr上升(P<0.05);③肾衰方组(CKD III期、IV期)肾功能在治疗后BUN、Scr下降,Ccr上升(P<0.05);④与羟苯磺酸钙组和肾衰方组比,肾衰方联合羟苯磺酸钙组疗效优于羟苯磺酸钙组(P<0.01)。结论:①肾衰方联合羟苯磺酸钙组对慢性肾脏疾病的疗效优于单独使用羟苯磺酸钙组或肾衰方。②肾衰方联合羟苯磺酸钙组对于血肌酐的作用明显优于尿素氮。③单独使用羟苯磺酸钙组或肾衰方对于慢性肾脏病Ⅴ期的患者肾功改善不明显。

Effects of Renal Failure Formula and Calcium Dobesilate on the Chronic Kidney Disease

Objective:To observe the effects of Renal Failure Formula and calcium dobesilate on the chronic kidney disease.Methods:Choose 120 patients with chronic renal insufficiacy and eGFR lower than 60mL/(min·1.73m2),and put them into three groups including 31 patients taking calcium dobesilate,59 patients taking Renal Failure Formula and calcium dobesilate and 30 patients taking Renal Failure Formula.The patients took 500mg of calcium dobesilate three times a day,50mL of Renal Failure Formula three times a day.Then observe the levels of serum creatinine(Scr),urea nitrogen(BUN)and creatinine clearance rate(Ccr)before treatment and after two weeks of treatment.Results:①In Renal Failure Formula and calcium dobesilate group,BUN level(P<0.01)and Scr level decreased(P<0.001),and Ccr went up obviously(P<0.001).②In calcium dobesilate group in the third and fourth stages,BUN level and Scr level decreased,and Ccr went up(P<0.05).③In Renal Failure Formula group in the third and fourth stages,BUN level and Scr level decreased,and Ccr went up(P<0.05).④Compared with calcium dobesilate group and Renal Failure Formula group,the curative effects in Renal Failure Formula and calcium dobesilate group were better than that in calcium dobesilate group(P<0.01).Conclusions:①The curative effect in Renal Failure Formula and calcium dobesilate group was better than that in Renal Failure Formula group and calcium dobesilate group.②Renal Failure Formula or calcium dobesilate could not obviously improve the patients in the fifth stage of chronic kidney disease.③Separate use of calcium dobesilate group or renal failure has no obvious improvement in patients with renal chronic kidney disease in stage Ⅴ.